Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Regeneron: How easy is it for ordinary Americans to access coronavirus treatment recommended by Trump?

US drugmaker requests approval for 50,000 doses of treatment used on president 

Gino Spocchia
Thursday 08 October 2020 09:23 EDT
Comments
Donald Trump posts new video from the White House

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Donald Trump has recommended another unproven coronavirus treatment called Regeneron and promised it would be delivered en masse without cost to Americans.

Making an appearance via video on Wednesday, the US president cited the treatment he received at Walter Reed Medical Centre, and promised he would soon approve its widespread use.

Doctors reportedly administered the 74-year-old president with the antibody treatment produced by Regeneron Pharmaceuticals Inc, and known as REGN-COV2, on compassionate grounds over the weekend.

“It's called Regeneron — and other things too — but I think this was the key,” said the president in a video. “But they gave me Regeneron and it was like unbelievable, I felt good immediately.”

The drug, which has not yet been approved to treat Covid-19 in the United States, is subject to clinical trials around the world and approval by the US Food and Drug Administration (FDA).

REGN-COV2 is made up of two monoclonal antibodies (REGN10933 and REGN10987), which are man-made and act like human antibodies in the immune system, helping to fight off the virus.

While recommending coronavirus patients to request the Regernon-produced treatment, Mr Trump claimed on Wednesday that he would seek widespread authorisation of the drug’s use.

“We’re trying to get them on an emergency basis. We’ve authorised it, I’ve authorised it, and if you're in the hospital and you're feeling really bad I think we’re going to work it so you can get ‘em free,” he said.

Mr Trump claimed on Wednesday that “we have hundreds of thousands of doses that are about ready”, however Regeneron announced that it was asking for FDA approval for some 50,000 doses to be delivered.   

An FDA spokesperson did not return comment to The New York Times on Regeneron’s application, with the agency supposed to make decisions independent of the White House.

The president’s doctor meanwhile claimed he had developed virus antibodies — a sign that could indicate his immune system’s response to Covid-19, or the antibodies delivered though his treatment regimen.

It is not clear at present when Regeneron’s drug will be approved.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in